New CEO appointed for Intervacc – a innovative and expanding vaccine company
Intervacc, a Swedish innovative vaccine company listed on Nasdaq First North, has appointed Andreas Andersson as CEO. The Company thus gains a valuable addition to lead the expansion and strategic development on the growth journey for a new generation of animal health vaccines. This appointment follows on the clinical success of Intervacc’s lead vaccine project Strangvac®. This strengthening of Intervacc is part of Intervacc's development and commercialization of animal vaccine based on the company's vaccine platform. Intervacc’s current CEO and co-founder, Professor Flock, will continue to lead the research, product development and clinical activities in the role as Chief Scientific Officer.
Andreas Andersson has previously held senior positions as CEO, General Manager and Sales Director in companies with a scientific and hi-tech focus, most recently at Biolin Scientific AB. Andreas Andersson holds a Master of Science in Industrial Engineering and Management from Linköping University.
“We are delighted with the appointment of Andreas. He has a track record of success in developing and expanding companies with a strong technology focus. This is an exciting time for Intervacc, as it prepares for the registration and commercialization of Stangvac® as well as the continued development of the Company’s other vaccine candidates.”, says Björn Sjöstrand, Chairman of the Board of Intervacc AB.
Andreas Andersson commented, "It's exciting to join Intervacc at this time as the Company has shown its ability to develop unique vaccines using its recombinant technology platform. I think Intervacc has the potential to become one of the leading, independent animal health vaccine businesses and I look forward to contribute to this effort.”
“I see it as a desired addition with Andreas included in the team. With him in place, I can now fully focus on the company's continued development and research activities, and not least the important registration process for Strangvac®. Intervacc is an innovative company with exciting future and this expansion will contribute to the company's continued success.” says Professor Jan-Ingmar Flock
Andreas Andersson’s starting date for the position as CEO of Intervacc AB is December 13th 2018.
For more information please contact:
Björn Sjöstrand, Chairman of the Board
E-mail: bjorn.sjostrand@scandinavianbiopharma.se
Phone: +46-72-712 51 20
This information is information that Intervacc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on December 12th, 2018.
About Intervacc
Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Tags:
